Ensysce Biosciences, Inc.

As of August 16, 2021, Ensysce Biosciences, Inc. is considered overvalued and risky due to negative financial metrics, including a Price to Book Value of 1.85 and significantly negative ROCE and ROE, indicating poor performance compared to peers like ContraFect Corp.

As of October 15, 2023, Ensysce Biosciences, Inc. is considered attractive and undervalued with a P/E ratio of 12.5 and a P/B ratio of 1.2, especially when compared to peers like Acadia Pharmaceuticals and Zymeworks, and its recent performance has outpaced the Sensex.

As of October 1, 2023, there is insufficient technical data for Ensysce Biosciences, Inc. to determine a bullish or bearish outlook.

Ensysce Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $2 million as of March 2025. The company has a market cap of $4.93 million and does not pay dividends.

As of Jun 18, Ensysce Biosciences, Inc. has a market capitalization of 4.93 million, with net sales of 6.22 million and a net profit of -6.82 million over the last four quarters. The company reported shareholder's funds of 3.71 million and total assets of 5.60 million as of Dec 24.